ClinicalTrials.gov
ClinicalTrials.gov Menu

Protective Effects of Sitagliptin on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes (LADA) (DPP-ⅣLADA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01159847
Recruitment Status : Completed
First Posted : July 12, 2010
Last Update Posted : July 31, 2018
Sponsor:
Collaborators:
Chinese Medical Association
Eli Lilly and Company
Information provided by (Responsible Party):
Zhiguang Zhou, Second Xiangya Hospital of Central South University

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : July 2012
  Actual Study Completion Date : December 2012
Publications:
Duttaroy A, Voelker F, Merriam LQ, et al. The DPP-4 inhibitor Vildagliptin increases pancreatic β-cell neogenesis and decreases apoptosis. Diabetes, 2005; 54 (Suppl. 1): A141.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):